Skip to content

Erasca

US · ERAS #2103 by market cap Listed 2021
13.61 -0.61 -4.29%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 15 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.5 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
89.41% -1.52pp
Institutions
309 +15
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund41.86%
Hedge Fund22.47%
VC/PE Fund20.59%
Individual/Insider9.65%
Public Company2.47%
Private Company0.76%
Sovereign Wealth Fund0.60%
Insurance Company0.43%
Government Pension Fund0.21%
Other0.96%

Top holders as of 2026-06-30

Jonathan Lim 9.25% · 32.36M sh
T. Rowe Price Group, Inc. 7.85% · 27.46M sh
Frazier Life Sciences Management, LP 7.14% · 24.98M sh
BlackRock 6.79% · 23.74M sh
RTW Investments, LP 5.13% · 17.95M sh
VR Management, LLC 5.12% · 17.89M sh
Vanguard Capital Management, LLC 3.98% · 13.91M sh
State Street Global Advisors 3.95% · 13.82M sh
Artal Group S.A. 3.77% · 13.20M sh
Logos Global Management, L.P. 3.47% · 12.15M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 38 buys · 12 sells

NameRoleStake
Jonathan Lim Chairperson & CEO 9.25%
Alexander Casdin Independent Director 0.19%
David Chacko CFO & Chief Business Officer 0.08%
James Bristol Lead Independent Director 0.06%
Pratik Multani Independent Director 0.05%
Ebun Garner Chief Legal Officer 0.01%
Valerie Harding-Start Independent Director 0.01%
Julie Hambleton Independent Director 0.00%
Jean I. Liu Independent Director --
Michael Varney Chairman of Research & Development, Scientific Advisory Board Member and Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-09 Charles Fuchs President of Research & Development Other Derivative Acquisition +1,300,000 $18.12
2026-06-25 Jean I. Liu Independent Director Other Derivative Acquisition +29,888 $16.01
2026-06-25 Alexander Casdin Independent Director Other Derivative Acquisition +29,888 $16.01
2026-06-25 Pratik Multani Independent Director Other Derivative Acquisition +29,888 $16.01
2026-06-25 James Bristol Lead Independent Director Other Derivative Acquisition +29,888 $16.01
2026-06-25 Julie Hambleton Independent Director Other Derivative Acquisition +29,888 $16.01
2026-06-25 Valerie Harding-Start Independent Director Other Derivative Acquisition +29,888 $16.01
2026-03-31 Ebun Garner Chief Legal Officer Derivative Exercise and Sale -80,000 $1.70–16.40
2026-03-03 Shannon Morris Chief Medical Officer Derivative Exercise and Sale -20,000 $1.70–15.04
2026-01-28 Michael Varney Chairman of Research & Development, Scientific Advisory Board Member and Director Other Derivative Acquisition +96,000 $10.31
2026-01-28 Jonathan Lim Chairperson & CEO Other Derivative Acquisition +2,000,000 $10.31
2026-01-28 Ebun Garner Chief Legal Officer Other Derivative Acquisition +560,000 $10.31
2026-01-28 Shannon Morris Chief Medical Officer Other Derivative Acquisition +625,000 $10.31
2026-01-28 David Chacko CFO & Chief Business Officer Other Derivative Acquisition +640,000 $10.31
2026-01-06 Ebun Garner Chief Legal Officer Derivative Exercise and Sale -120,000 $1.70–5.59
2025-12-31 Jean I. Liu Independent Director Other Derivative Acquisition +20,617 $3.72
2025-12-31 Alexander Casdin Independent Director Other Derivative Acquisition +23,872 $3.72
2025-12-31 Pratik Multani Independent Director Other Derivative Acquisition +19,532 $3.72
2025-12-31 James Bristol Lead Independent Director Other Derivative Acquisition +37,762 $3.72
2025-12-31 Valerie Harding-Start Independent Director Other Derivative Acquisition +24,306 $3.72

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Erasca discussion 0 comments

Add a comment